Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 15, 2017

Study Completion Date

March 22, 2018

Conditions
Refractory Multiple Myeloma
Interventions
DRUG

pomalidomide

Given orally

DRUG

bortezomib

Given IV

DRUG

dexamethasone

Given orally

OTHER

laboratory biomarker analysis

Optional correlative studies

OTHER

gene expression analysis

Optional correlative studies

Trial Locations (3)

55905

Mayo Clinic, Rochester

Unknown

Mayo Clinic in Arizona, Scottsdale

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER